財報速遞
10月28日,中國人民保險集團(01339)發佈季度業績。實現營業收入約1389.85億元;歸屬於母公司股東的淨利潤爲38.91億元;基本每股收益爲0.09元;稀釋每股收益約爲0.09元;公司總資產爲1.36萬億元,比2020年12月末增加8.24%;歸屬於母公司股東的股東權益爲2140.77億元,比2020年12月末增加5.88%。
中國人民保險集團在過去5個交易日累計下跌0.40%,最新價格爲2.43港元。
根據盈立智投的趨勢長盈策略監控,在一個月內,中國人民保險集團出現過2次關注信號,1次觀望信號,其中最近一次是10月19日出現關注信號。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.